AbbVievsNasus Pharma

ABBV and NSRX stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $525B and Nasus Pharma (NSRX) $24M. Over the last year, with dividends, ABBV moved +31.6% and NSRX -64.1%. Dividend yield: ABBV 2.33%, NSRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$525B

    NSRX$24M

    ABBV is 21,907 times NSRX

  • Revenue, 12 months

    ABBV$66.0B

    NSRX$1.2B

    ABBV is 53 times NSRX

  • Net income, 12 months

    ABBV$10.3B

    NSRX-$5.9M

  • Operating margin

    ABBV32.2%

    NSRX-0.4%

    32.6 points apart

  • ROIC

    ABBV25.7%

    NSRX-140.0%

    165.7 points apart

  • P/E

    ABBV51.0

    NSRX–

  • Dividend yield

    ABBV2.3%

    NSRX0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+31.6%

NSRX-64.1%

50100DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsNSRXWith dividends
1 year since November 14, 2025+31.6%Price +27.8%-64.1%Price -64.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieNSRXNasus Pharma

Valuation

ABBVNSRX
Valuation
Price$297.11$2.66
Market value$525B$24M
Enterprise value (EV)$595B$23M
P/E51.0–
P/E, 5-year median57.0–
P/B–8.7
EV/EBIT28.0–
Free cash flow yield3.6%–

Results and growth

ABBVNSRX
Results and growth
Revenue, 12 months$66.0B$1.2B
Net income, 12 months$10.3B-$5.9M
Free cash flow, 12 months$18.9B-$4.9M
Earnings per share, 12 months$5.81-$0.72
Revenue growth, year on year8.6%–
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVNSRX
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-0.4%
Net margin15.7%-0.5%
ROIC25.7%-140.0%
ROE––

Balance sheet

ABBVNSRX
Balance sheet
Cash$10.8B$1.2M
Total debt$80.9B$118.0K
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVNSRX
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or NSRX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Nasus Pharma?

By market value, AbbVie ($525B) is about 21,906.6 times Nasus Pharma ($24M), at today's prices.

How did ABBV and NSRX stock do over the last 1 years?

Since November 14, 2025, ABBV's price moved +27.8% and NSRX's -64.1%. With dividends: ABBV +31.6% (+31.6% a year), NSRX -64.1% (-64.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or NSRX?

The dividend yield at today's price is 2.33% for AbbVie and none for Nasus Pharma. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Nasus Pharma?

Over the last twelve months, the net margin was 15.7% for AbbVie and -0.5% for Nasus Pharma, and the operating margin 32.2% and -0.4%. Revenue was $66.0B and $1.2B.

Which is the better investment, AbbVie or Nasus Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.